p53 and Ralbp1 in Carcinogenesis
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 12496
Special Issue Editor
2. Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX 79415, USA
Interests: glutathione-mediated xenobiotic metabolism and transport of glutathionylated metabolites; oxidative stress; EGFR; Ral; Ras; Rac; Rho; MEK; ERK; MYC; p53; Rb; mTOR; AKT; PI3K; JAK/STAT; VHL; WNT and Ca pathway signaling; epigenetic regulation of gene expression; carcinogenesis; oncogenic and tumor suppressor pathways; transport mediated cancer drug resistance; radiation resistance; cancer therapy (all sites and histologies)
Special Issue Information
Dear Colleagues,
In humans, genetic lesions that cause loss of TP53, a stress-responsive tumor suppressor protein, causes the Li-Fraumeni hereditary cancer syndrome in humans. Spontaneous cancer develop in nearly all TP53-null mice before 6 months of age. In stark contrast, mice lacking the stress-responsive mercapturic acid pathway ATPase enzyme Ralbp1 (which encodes the 76 kDa protein, RLIP76 aka Rlip) are resistant to carcinogenesis even upon exposure to the most potent chemical carcinogens. We discovered that haploinsufficiency of Rlip can switch off spontaneous carcinogenesis in p53 null mice and cause reversion of their gene promoter methylation defects to wild-type. Because of the pleiotropic functions of both p53 and Rlip, the mechanism of this observations remain unclear. Thus, we have invited scientists studying the various functions and cancer signaling pathways linked to Rlip and p53 to contribute to a discussion that may help elucidate the underlying molecular mechanisms.
Prof. Dr. Sanjay Awasthi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ralbp1/Rlip76Rlip
- TP53/p53
- carcinogenesis
- glutathione
- oxidative stress
- 4-hydroxynonenal
- checkpoint regulation
- DNA methylation
- clathrin-dependent endocytosis
- vesicle trafficking